DSpace logo

Please use this identifier to cite or link to this item: http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13337
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMurugesan, Sankaranarayanan-
dc.date.accessioned2023-12-11T07:06:53Z-
dc.date.available2023-12-11T07:06:53Z-
dc.date.issued2022-01-
dc.identifier.urihttps://www.future-science.com/doi/10.4155/fmc-2021-0237-
dc.identifier.urihttp://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13337-
dc.description.abstractLiterature reports suggest spirochromanone derivatives exhibit anticancer activity. Methodology: The authors designed and synthesized 18 spirochromanone derivatives (Csp 1–18). The compounds were characterized and evaluated for anticancer activity against human breast cancer (MCF-7) and murine melanoma (B16F10) cell lines. Results: The anticancer activity ranged from 4.34 to 29.31 μm. The most potent compounds, Csp 12 and Csp 18, were less toxic against the human embryonic kidney (HEK-293) cell line and ∼ two/∼fourfold selective toward MCF-7 than B16F10 in comparison to the reference, BG-45. Csp 12 caused 28.6% total apoptosis, leading to significant cytotoxicity, and arrested the G2 phase of the cell cycle in B16F10 cells. A molecular docking study of Csp 12 exhibited effective binding at the active site of the epidermal growth factor receptor kinase domain. Conclusion: This study highlights the importance of spirochromanones as anticancer agents.en_US
dc.language.isoenen_US
dc.publisherFuture Science Groupen_US
dc.subjectPharmacyen_US
dc.subjectAnticanceren_US
dc.subjectApoptosisen_US
dc.subjectCytotoxicityen_US
dc.subjectMolecular dockingen_US
dc.subject4′-piperidine]-4-oneen_US
dc.titleDesign, synthesis and structure–activity relationship studies of novel spirochromanone hydrochloride analogs as anticancer agentsen_US
dc.typeArticleen_US
Appears in Collections:Department of Pharmacy

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.